| Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency (NCT05222178) | Homology Medicines, Inc | 2022-06-03 |
| A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria (NCT05166161) | PTC Therapeutics | 2022-02-14 |
| A Study of PTC923 in Participants With Phenylketonuria (NCT05099640) | PTC Therapeutics | 2021-09-30 |
| Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria (NCT04879277) | University Hospital, Tours | 2021-05-26 |
| Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria (NCT04534842) | Synlogic | 2020-08-25 |
| Long-Term Follow Up Study of Subjects Previously Administered HMI 102 (NCT04348708) | Homology Medicines, Inc | 2020-08-19 |
| Phenylalanine and Its Impact on Cognition (NCT03788343) | Insel Gruppe AG, University Hospital Bern | 2019-08-19 |
| Protein Requirements in Adults With Phenylketonuria (PKU) (NCT03939052) | University of British Columbia | 2019-07-19 |
| Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU) (NCT04085666) | Société des Produits Nestlé (SPN) | 2019-06-01 |
| SNAP: Study Nutrients in Adult PKU (NCT03858101) | Nutricia Research | 2019-04-15 |
| Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria (NCT03516487) | Synlogic | 2018-04-17 |
| The Effectiveness of Kuvan in Amish PKU Patients (NCT02677870) | University Hospitals Cleveland Medical Center | 2018-01-22 |
| Evaluation of PKU Explore (NCT03168399) | Vitaflo International, Ltd | 2017-06-08 |
| Evaluation of PKU Start (NCT03058848) | Vitaflo International, Ltd | 2017-03-06 |
| GMP Drink for PKU Study (NCT02915510) | Nutricia UK Ltd | 2016-07-01 |
| Simplified Diet Approach in Phenylketonuria (NCT02555579) | University of Nebraska | 2015-10-26 |
| A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302 (NCT02468570) | BioMarin Pharmaceutical | 2015-08-05 |
| The Brain and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria (NCT02297347) | Boston Children's Hospital | 2015-04-01 |
| Observational Study of Endothelial Dysfunction in Phenylketonuria (NCT02176603) | Charite University, Berlin, Germany | 2014-05-01 |
| Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria (NCT01977820) | BioMarin Pharmaceutical | 2014-02-01 |
| Protein Requirements in Children With Phenylketonuria (PKU) (NCT01965691) | University of British Columbia | 2013-10-01 |
| Kuvan®'s Effect on the Cognition of Children With Phenylketonuria (NCT01965912) | BioMarin Pharmaceutical | 2013-10-01 |
| Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study (NCT01924026) | The Hospital for Sick Children | 2013-09-01 |
| The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study (NCT01917344) | Boston Children's Hospital | 2013-08-01 |
| An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165 (NCT01819727) | BioMarin Pharmaceutical | 2013-05-01 |
| Moderate Intensity Exercise and Phenylketonuria (NCT01904708) | Oregon Health and Science University | 2013-05-01 |
| Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia (NCT01869972) | Hamilton Health Sciences Corporation | 2013-05-01 |
| Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria (NCT01732471) | Merck KGaA, Darmstadt, Germany | 2012-11-01 |
| A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks (NCT01560286) | BioMarin Pharmaceutical | 2012-05-01 |
| Liver Cell Transplant for Phenylketonuria (NCT01465100) | Ira Fox | 2011-10-12 |
| Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria (NCT01428258) | University of Wisconsin, Madison | 2011-09-01 |
| Phenylketonuria, Oxidative Stress, and BH4 (NCT01395394) | Emory University | 2011-06-01 |
| Kuvan® in Phenylketonuria Patients Less Than 4 Years Old (NCT01376908) | BioMarin Pharmaceutical | 2011-06-01 |
| Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy (NCT01541397) | The University of Texas Health Science Center, Houston | 2011-06-01 |
| Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU) (NCT01212744) | BioMarin Pharmaceutical | 2011-03-01 |
| Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients (NCT01114737) | BioMarin Pharmaceutical | 2010-08-01 |
| Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period (NCT01082328) | Merck KGaA, Darmstadt, Germany | 2010-05-01 |
| Follow-up of Adult Phenylketonuria (PKU) Patients (NCT01096758) | Ludwig-Maximilians - University of Munich | 2010-03-01 |
| Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy (NCT00986973) | Children's Hospital of Philadelphia | 2010-03-01 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003) (NCT00924703) | BioMarin Pharmaceutical | 2010-01-13 |
| Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU (NCT00925054) | BioMarin Pharmaceutical | 2009-09-01 |
| The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU) (NCT00964236) | University of Missouri-Columbia | 2009-08-01 |
| Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria (NCT00909012) | Ludwig-Maximilians - University of Munich | 2009-05-01 |
| Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU (NCT00838435) | BioMarin Pharmaceutical | 2009-02-01 |
| Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response (NCT00841100) | University of Miami | 2008-12-01 |
| Nutritional and Neurotransmitter Changes in PKU Subjects on BH4 (NCT00688844) | Emory University | 2008-10-01 |
| A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects (NCT00789568) | BioMarin Pharmaceutical | 2008-10-01 |
| Study to Evaluate the Effects of Kuvan on Individuals With Phenylketonuria (PKU) With Maladaptive Behaviors (NCT00728676) | Shoji Yano | 2008-08-01 |
| Sapropterin in Individuals With Phenylketonuria (NCT00730080) | Washington University School of Medicine | 2008-07-01 |
| Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria (NCT00634660) | BioMarin Pharmaceutical | 2008-05-01 |
| The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU) (NCT00892554) | Emory University | 2007-06-01 |
| Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006 (NCT00332189) | BioMarin Pharmaceutical | 2006-07-01 |
| The Early History of Universal Screening for Metabolic Disorders (NCT00309400) | University of Miami | 2006-01-01 |
| Response to Phenylketonuria to Tetrahydrobiopterin (BH4) (NCT00244218) | The University of Texas Medical Branch, Galveston | 2005-04-01 |
| Study of BH4, a New and Simple Treatment of Mild PKU (NCT00260000) | The Kennedy Institute-National Eye Clinic | 2005-04-01 |
| Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria (NCT01659749) | Emory University | 1995-06-01 |
| Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU) (NCT00065299) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1984-05-01 |
| Study of a Phenylalanine Restricted Diet During Pregnancy to Prevent Symptoms in Offspring of Patients With Phenylketonuria (NCT00006142) | National Center for Research Resources (NCRR) | 1983-12-01 |
| Sapropterin Expanded Access Program (NCT00484991) | BioMarin Pharmaceutical | |